Charles River Laboratories International, Inc. (NYSE:CRL) Position Reduced by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 12.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,352 shares of the medical research company's stock after selling 5,634 shares during the quarter. Janney Montgomery Scott LLC owned 0.08% of Charles River Laboratories International worth $7,264,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Mitchell & Pahl Private Wealth LLC raised its position in shares of Charles River Laboratories International by 8.8% during the 4th quarter. Mitchell & Pahl Private Wealth LLC now owns 3,603 shares of the medical research company's stock valued at $665,000 after buying an additional 292 shares during the period. Kera Capital Partners Inc. purchased a new stake in shares of Charles River Laboratories International during the fourth quarter worth $246,000. Pinnacle Bancorp Inc. raised its holdings in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. Fiduciary Financial Group LLC lifted its holdings in Charles River Laboratories International by 3.9% during the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after buying an additional 63 shares during the last quarter. Finally, Czech National Bank increased its stake in Charles River Laboratories International by 5.4% in the fourth quarter. Czech National Bank now owns 11,088 shares of the medical research company's stock valued at $2,047,000 after purchasing an additional 571 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CRL has been the subject of several recent research reports. CLSA downgraded Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target for the company. in a report on Monday, November 18th. StockNews.com downgraded shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. The Goldman Sachs Group cut their price objective on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a "sell" rating and a $151.00 price target for the company. Finally, Bank of America dropped their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $204.38.

Charles River Laboratories International Stock Down 1.2 %

Shares of NYSE CRL traded down $1.96 on Wednesday, hitting $161.68. The company had a trading volume of 560,891 shares, compared to its average volume of 963,833. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 12-month low of $159.65 and a 12-month high of $275.00. The firm has a market capitalization of $8.27 billion, a P/E ratio of 20.24, a PEG ratio of 5.94 and a beta of 1.38. The business has a 50 day moving average of $185.35 and a two-hundred day moving average of $196.24.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period in the prior year, the firm earned $2.72 earnings per share. The business's quarterly revenue was down 1.6% compared to the same quarter last year. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Insider Activity

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).